Is today’s [announcement] still regarding a diagnostic device that goes into Brainlab’s pot to reduce the gross margin target, as it did last year? Has the reporting in this regard been clarified for this year? In other words, do the diagnostic devices announced by Nexstim, which have not been clearly excluded by contract, still affect Brainlab’s gross margin target?
1 Like